论文部分内容阅读
目的 :观察β2 整合素 (CD11a、CD11b)及选择素 (CD62L)在恶性血液病的表达及其与细胞分型 ,临床特征的关系。方法 :用流式细胞仪检测 2 5例急性髓系白血病 (acutemyeloidleukemia ,AML) ,18例急性淋巴系白血病(acutelymphocyticleukemia ,ALL) ,10例慢性粒细胞性白血病 (chronicmyelocyticleukemia ,CML) ,15例多发性骨髓瘤 (multiplemyeloma ,MM ) ,15例非何杰金氏淋巴瘤 (non Hodgkinslymphoma ,NHL)及 15例正常人骨髓单个核细胞CD11a、CD11b及CD62L的表达。结果 :(1)与正常人骨髓单个核细胞相比 ,多发性骨髓瘤、恶性淋巴瘤三种粘附分子表达无明显改变。急性髓性白血病细胞表面粘附分子CD11b、CD62L表达下降 ,急性淋巴细胞白血病细胞CD11a、CD11b表达下降而CD62L表达则增加 ,慢性粒细胞性白血病细胞CD11b增加。 (2 )部分粘附分子与细胞类型有关 ,CD11b、CD62L在M1～M3 的表达低于在M4 、M5型表达 ,CD11a在B ALL表达明显低于T ALL表达。 (3)对于AML细胞三种粘附分子CD62L、CD11a、CD11b之间的有明显相关性 (P <0 0 5 )。 (4)粘附分子与部分临床特征有相关性。结论 :不同的恶性血液病粘附分子CD11a、CD11b、CD62L的表达存在不同的改变并与细胞类型、临床特征有关。
Objective: To observe the expression of β2 integrin (CD11a, CD11b) and selectin (CD62L) in hematological malignancies and its relationship with cell type and clinical characteristics. METHODS: Fifty-five patients with acute myeloid leukemia (AML), 18 acute lymphatic leukemia (acute lymphocytic leukemia, ALL) and 10 chronic myeloid leukemia (CML) were detected by flow cytometry. Multiple myeloma (MM), 15 non-Hodgkins lymphoma (NHL) and 15 normal human bone marrow mononuclear cells CD11a, CD11b and CD62L expression. Results: (1) Compared with normal bone marrow mononuclear cells, the expression of three adhesion molecules in multiple myeloma and malignant lymphoma did not change significantly. The expression of CD11b and CD62L on the surface of acute myeloid leukemia was decreased. The expression of CD11a and CD11b in acute lymphoblastic leukemia cells decreased while the expression of CD62L increased. CD11b increased in chronic myelogenous leukemia cells. (2) Part of the adhesion molecules was related to cell type. The expression of CD11b and CD62L in M1 to M3 was lower than that in M4 and M5. The expression of CD11a in B ALL was significantly lower than that of T ALL. (3) There was a significant correlation between the three adhesion molecules CD62L, CD11a, and CD11b in AML cells (P < 0.05). (4) There is a correlation between adhesion molecules and some clinical features. Conclusion: The expressions of CD11a, CD11b, and CD62L have different changes in different hematological malignancies and are related to cell type and clinical characteristics.